Pushing against cancer

CAMBRIDGE, U.K.—In September, Crescendo Biologics Ltd., a developer of novel, targeted T cell-enhancing therapeutics, announced that it had signed collaborations with world-renowned oncology research groups at the University of Oxford and the University of Surrey. These collaborations will accelerate the development of CB307, Crescendo’s lead program for PSMA-positive tumors, and its follow-on pipeline of CD137-directed T cell-enhancing programs.

The Department of Oncology at the University of Oxford is one of the top cancer research centers globally. Dr. Kerry Fisher’s group within this department, focuses on deepening the understanding of the tumor microenvironment to develop innovative new therapies for cancer patients.

And at the University of Surrey, Prof. Hardev Pandha is a clinician scientist and a medical oncologist, as well as head of the university’s Targeted Cancer Therapy research group, director of the Surrey Cancer Research Institute and an expert in the management of patients with urological cancers. Pandha leads a highly respected team with key interests in early-phase clinical trials with targeted agents and novel therapies in translational settings.

“Prof. Pandha and Dr. Fisher each head up world-leading groups—it is a credit to the quality of our science to be able to collaborate with them,” said Theodora Harold, CEO of Crescendo Biologics. “Their multidisciplinary and collaborative approaches to oncology research will allow Crescendo to gain a greater understanding of these difficult to treat cancers and support us to deliver first-in-class, targeted T cell therapies.”